Hepatitis B virus reactivation and alemtuzumab therapy

Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A

Risultato della ricerca: Article

94 Citazioni (Scopus)

Abstract

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.
Lingua originaleEnglish
pagine (da-a)254-258
Numero di pagine5
RivistaEuropean Journal of Haematology
Volume74
Stato di pubblicazionePublished - 2005

Fingerprint

Hepatitis B Surface Antigens
Hepatitis B virus
Lamivudine
Hepatitis B
DNA
Therapeutics
Antibodies, Monoclonal, Humanized
Virus Diseases
B-Cell Chronic Lymphocytic Leukemia
Infection
Immunotherapy
Immunosuppression
Hepatitis
Epitopes
Lymphocytes
alemtuzumab
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology

Cita questo

Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A (2005). Hepatitis B virus reactivation and alemtuzumab therapy. European Journal of Haematology, 74, 254-258.

Hepatitis B virus reactivation and alemtuzumab therapy. / Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A.

In: European Journal of Haematology, Vol. 74, 2005, pag. 254-258.

Risultato della ricerca: Article

Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A 2005, 'Hepatitis B virus reactivation and alemtuzumab therapy', European Journal of Haematology, vol. 74, pagg. 254-258.
Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A. Hepatitis B virus reactivation and alemtuzumab therapy. European Journal of Haematology. 2005;74:254-258.
Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A. / Hepatitis B virus reactivation and alemtuzumab therapy. In: European Journal of Haematology. 2005 ; Vol. 74. pagg. 254-258.
@article{495f1e6131ff48778dd210fa56033fd8,
title = "Hepatitis B virus reactivation and alemtuzumab therapy",
abstract = "Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53{\%} of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.",
keywords = "Alemtuzumab; Campath-1H; hepatitis B virus; acute hepatitis; lamivudine; chronic lymphocytic leukaemia",
author = "{Iannitto,E; Minardi,V; Mul{\`e},A; Trapani, Rd; Crax{\`i},A} and Vincenzo Abbadessa and {Di Stefano}, Rosa and Antonio Craxi and Donatella Ferraro and Emanuele Ammatuna and Giuseppina Calvaruso and Antonino Mule'",
year = "2005",
language = "English",
volume = "74",
pages = "254--258",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Hepatitis B virus reactivation and alemtuzumab therapy

AU - Iannitto,E; Minardi,V; Mulè,A; Trapani, Rd; Craxì,A

AU - Abbadessa, Vincenzo

AU - Di Stefano, Rosa

AU - Craxi, Antonio

AU - Ferraro, Donatella

AU - Ammatuna, Emanuele

AU - Calvaruso, Giuseppina

AU - Mule', Antonino

PY - 2005

Y1 - 2005

N2 - Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.

AB - Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.

KW - Alemtuzumab; Campath-1H; hepatitis B virus; acute hepatitis; lamivudine; chronic lymphocytic leukaemia

UR - http://hdl.handle.net/10447/44311

M3 - Article

VL - 74

SP - 254

EP - 258

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -